



12<sup>th</sup> August, 2024

Corporate Relationship Department  
M/s. BSE Ltd.  
Dalal Street, Fort  
**Mumbai – 400 001.**  
Scrip Code: **524816**

The Manager – Listing  
M/s. National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra-Kurla Complex  
Bandra(E), **MUMBAI – 400 051.**  
Scrip Code: **NATCOPHARM**

Dear Sir/Madam

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015**

Pursuant to Regulation 30 read with Schedule III Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that among other items of business the Board of Directors based on the recommendation of Nomination and Remuneration Committee/Audit Committee, at its meeting held on 12<sup>th</sup> August, 2024 has, inter alia:

- (i) Approved the appointment of Sri Lakshminarayana Bolisetty (DIN: 02766709) as an Independent Director of the Company for a period of five (5) years w.e.f. 12<sup>th</sup> August, 2024.
- (ii) Approved the appointment of Smt. Kantipudi Suma (DIN: 02734369) as an Independent Director of the Company for a period of five (5) years w.e.f. 12<sup>th</sup> August, 2024.
- (iii) Approved the appointment of Sri Nitin Jain (DIN: 00136245) as Independent Director of the Company for a period of five (5) years w.e.f. 12<sup>th</sup> August, 2024.
- (iv) Approved the appointment of M/s. B S R and Co (ICAI FRN: 128510W), Chartered Accountants as Statutory Auditors of the Company in place of M/s. B S R & Associates LLP (ICAI FRN: 116231W/W-100024) for a period of five (5) years i.e., from the conclusion of the 41st Annual General Meeting till 46th Annual General Meeting of the Company to be held for the Financial Year 2028-29.

The Board of Directors of the Company also took note of Dr. T.V. Rao (DIN: 05273533), Independent Director completing his second term of 5 years as an Independent Director of the Company w.e.f. 24<sup>th</sup> August, 2024 and Dr. Leela Digumarti (DIN: 06980440), Independent Director completing her second term of 5 years as an Independent Director of the Company w.e.f. 21<sup>st</sup> September, 2024.

We hereby confirm that all the above-mentioned Appointed Director(s) are not debarred from holding the office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such authority.



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, [www.natcopharma.co.in](http://www.natcopharma.co.in)

The aforesaid appointment(s) are subject to approval of Shareholders. The Board decided to seek the approval of the Shareholders of the Company at the ensuing Annual General Meeting.

The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are annexed as **Annexure**

This is for your information and records.

Thanking you

Yours faithfully,  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer

Encl: As above



The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is as under:

Sl. No.	Particulars			
1	Name	1) Sri Lakshminarayana Bolisetty	2) Dr. Kantipudi Suma	3) Sri Nitin Jain
2	Reason for change	Appointment as an Independent Director of the Company	Appointment as an Independent Director of the Company	Appointment as an Independent Director of the Company
3	Date of appointment/ reappointment/ cessation (as applicable) & term of appointment/reappointment	With effect from 12 <sup>th</sup> August, 2024 for a period of five years, subject to approval of the shareholders of the Company.	With effect from 12 <sup>th</sup> August, 2024 for a period of five years, subject to approval of the shareholders of the Company.	With effect from 12 <sup>th</sup> August, 2024 for a period of five years, subject to approval of the shareholders of the Company.
4	Brief profile (in case of appointment)	<p>Sri Lakshminarayana Bolisetty had an illustrious career in Banking &amp; Financial Sector having headed two important Zones of Corporation Bank namely Hyderabad &amp; Mumbai, also Headed Investment &amp; International Banking Division of the Bank. Also functioned as Head of Inspection &amp; Audit, Chief Compliance Officer, Head of Integrated Treasury of the Bank, Head of Planning &amp; Development, Head of Branch expansion, in the position as General Manager.</p> <p>He also worked as Company Secretary &amp; Head of Investor Relations Department and handled independently the private placement of equity of Corporation</p>	<p>Dr. Suma is a renowned Gynecologist &amp; Infertility specialist is a pioneer in Pre-implantation genetic diagnosis (PGD), In-vitro fertilization (IVF) &amp; Novel Stem cell culturing methodologies. In the last three decades, she has delivered over 5,000 babies and treated over 500 infertility couples. She has also been closely associated in advanced research of cell-based therapies with the Centre for Cellular &amp; Molecular Biology (CCMB) and the Centre for DNA Finger printing and Diagnostics (CDFD).</p> <p>She did her Bachelor of Medicine &amp; Surgery (MBBS) from Gandhi Medical College, Hyderabad, Diploma in Gynaecology and</p>	<p>Sri Nitin Jain has overall experience of 35 years which includes 20+ years of having co-founded and led a mid-sized boutique Investment Banking Practice; a brief stint of about 2 years heading Corporate Finance as part of the Investment Banking initiative at HDFC Bank Ltd.</p> <p>He has the track record of developing and implementing strategic initiatives for capitalizing on emerging opportunities and delivering on growth metrics in sync with evolving business requirements. He has demonstrated leadership and managerial capabilities in achieving Corporate Objectives, implementing strategies &amp; building coalitions to support business growth and implement &amp; manage change to drive organizational performance. Adept at interacting and liaising with C-Level</p>



Annexure

		<p>Bank to the extent of 27% to Life Insurance Corporation of India and due to his interest in academics he conducted training classes in banking and investments at Banking Training Colleges and ICAI University.</p> <p>He held the position of CEO &amp; CFO at Meliora Asset Reconstruction Company Ltd which deals with Stressed Assets of Banks which was one of the 28 Asset Reconstruction Company's in the country.</p>	<p>Obstetrics from Mysore Medical College, Mysore, Post Graduate M.D., Ob-Gyn from JJMMC, Davanagere, Karnataka, Fellowship in Reproductive Endocrinology, Infertility &amp; Obstetric Sonography from Mediscan Institute, Chennai, Fatal Medicine Diploma from UCL London, Diploma in Advanced Endoscopic Surgery and Hysteroscopy from KEIL's School of Endoscopy, Germany and Pre-Implantation Genetic Diagnosis &amp; Embryo Biopsy from UCL London.</p>	<p>decision makers of companies Pan India having handled multiple transactions from initiation unto closure and building trusted &amp; enduring relationships in the process.</p> <p>Currently he is the Managing Director at Nine Rivers Capital LLP, Mumbai which offers bespoke advisory solutions to corporates seeking support for equity capital raise, M&amp;A, and valuations. It acts as a trusted independent advisor to its clients, combining sector expertise and sharp execution to deliver successful outcomes.</p>
5	Disclosure of relationships between directors (in case of appointment of a director)	He is not related to any of the Director.	She is not related to any of the Director.	He is not related to any of the Director.
6	Information as required pursuant to BSE Circular no. LIST/COMP/14/2018- 19 & NSE circular no. NSE/CML/2018/24, dated June 20, 2018	He is not debarred from holding the office of Director pursuant to any SEBI Order or Order of any such Authority.	She is not debarred from holding the office of Director pursuant to any SEBI Order or Order of any such Authority.	He is not debarred from holding the office of Director pursuant to any SEBI Order or Order of any such Authority.



Sl. No.	Particulars		
1	Name	4) Sri T V Rao	5) Smt. Dr Leela Digumarti
2	Reason for change	Completion of second term of five years	Completion of second term of five years
3	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	With effect from 24 <sup>th</sup> August, 2024	With effect from 21 <sup>st</sup> September, 2024
4	Brief profile (in case of appointment)	Not Applicable	Not Applicable
5	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable	Not Applicable
6	Information as required pursuant to BSE Circular no. LIST/COMP/14/2018-19 & NSE circular no. NSE/CML/2018/24, dated June 20, 2018	Not Applicable	Not Applicable



Sl No.	Particulars		
1	Name	M/s. B S R & Associates LLP (ICAI FRN: 116231W/W-100024)	M/s. B S R and Co (ICAI FRN: 128510W)
2	Reason for change	Completion of tenure	Appointment of Statutory Auditors
3	Date of appointment/ reappointment/ cessation (as applicable) & term of appointment/reappointment	1 <sup>st</sup> October, 2024	To hold the office from the date of conclusion of the 41 <sup>st</sup> Annual General Meeting till the conclusion of the 46 <sup>th</sup> Annual General Meeting of the Company to be held for the financial year 2028-29, subject to approval of the shareholders of the Company.
4	Brief profile (in case of appointment)	Not Applicable	<p>B S R and Co ('the firm') was constituted on 01<sup>st</sup> September, 2007 as a partnership firm having firm registration no. as 128510W. The registered office of the firm is at 14<sup>th</sup> Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Centre, Western Express Highway, Goregaon (East), Mumbai-400063.</p> <p>B S R and Co is a member entity of B S R &amp; Affiliates, a network registered with the Institute of Chartered Accountants of India. It is registered at Mumbai, Gurgaon, Bangalore and Hyderabad. B S R and Co together with its member firms has around 4000+ staff and 200+ Partners.</p> <p>B S R member firms audits various Companies listed on Stock Exchanges in India including companies in the Lifesciences sector.</p>
5	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable	Not Applicable